G-quadruplex ligands mediate downregulation of DUX4 expression

  title={G-quadruplex ligands mediate downregulation of DUX4 expression},
  author={Lukasz Ciszewski and Ngoc B Lu-Nguyen and Alex Slater and Andrew Brennan and Huw E L Williams and George Dickson and M. S. Searle and Linda J Popplewell},
  journal={Nucleic Acids Research},
  pages={4179 - 4194}
Abstract Abnormal DUX4 expression in skeletal muscles plays a key role in facioscapulohumeral muscular dystrophy (FSHD) pathogenesis, although the molecular mechanisms regulating DUX4 expression are not fully defined. Using bioinformatic analysis of the genomic DUX4 locus, we have identified a number of putative G-quadruplexes (GQs) forming sequences. Their presence was confirmed in synthetic oligonucleotiode sequences derived from the enhancer, promoter and transcript of DUX4 through circular… Expand
6 Citations

Figures and Tables from this paper

Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model
It is demonstrated that further development of the antisense chemistries enhances in vitro antisense efficacy and that the optimized antisense approach has potential of being further developed as a therapeutic strategy for FSHD. Expand
Control of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Cancer.
This review discusses multiple levels of control of DUX4 expression, including enhancer-promoter interactions, DNA methylation, histone modifications, noncoding RNAs, and telomere positioning effect, and connects disparate data on intrachromosomal contacts involving Dux4. Expand
The prospects of targeting DUX4 in facioscapulohumeral muscular dystrophy
With emerging clinical trials, the clinical benefit from DUX4 repression in FSHD will likely soon become apparent and more efforts should be made to test them in vivo for clinical translation. Expand
Therapeutic Strategies Targeting DUX4 in FSHD
Different research areas that are currently being considered to alter DUX4 expression and toxicity in muscle tissue and the cell and animal models designed to date are discussed. Expand
Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update
There remains an incomplete understanding of the pathophysiology of FSHD in relation to the molecules leading to DUX4 gene activation and the downstream gene targets of Dux4 that cause its toxic effects. Expand
Current Genetic Survey and Potential Gene-Targeting Therapeutics for Neuromuscular Diseases
The current development of gene therapy is reviewed and focus on NMDs that are available in published reports, including Duchenne Muscular Dystrophy, Becker muscular dystrophy (BMD), X-linked myotubular myopathy (XLMTM), Spinal Muscular Atrophy (SMA), and Limb-girdle muscular dystrophies Type 2C (LGMD2C). Expand


The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein
It is proposed that DUX4-mediated cell death contributes to the pathogenic pathway in FSHD and is endogenously expressed in nuclei of adult and fetal human rhabdomyosarcoma cell lines. Expand
RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy.
  • L. Wallace, J. Liu, +5 authors S. Harper
  • Biology, Medicine
  • Molecular therapy : the journal of the American Society of Gene Therapy
  • 2012
A preclinical RNA interference (RNAi)-based DUX4 gene silencing approach as a prospective treatment for FSHD was tested and it was found that adeno-associated viral vector-delivered therapeutic microRNAs corrected Dux4-associated myopathy in mouse muscle. Expand
Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD)
It is shown in primary cultures that DUX4-targeted AOs suppress the atrophic FSHD myotube phenotype; but do not improve the disorganized FSHd myotubes phenotype which could be caused by DUX 4c over-expression. Expand
Myogenic Enhancers Regulate Expression of the Facioscapulohumeral Muscular Dystrophy-Associated DUX4 Gene
The data support a model in which these myogenic enhancers associate with the DUX4 promoter in skeletal myocytes and activate transcription when epigenetically derepressed in FSHD, resulting in the pathological misexpression of Dux4-fl. Expand
DUX4 and DUX4 downstream target genes are expressed in fetal FSHD muscles.
Results indicate that molecular markers of the disease are already expressed during fetal life, thus opening a new field of investigation for mechanisms leading to FSHD. Expand
DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?
Together the diffusion and the deregulation cascade would explain how a rare protein could cause the muscle defects observed in FSHD. Expand
DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy.
It is shown that DUX4 binds and activates LTR elements from a class of MaLR endogenous primate retrotransposons and suppresses the innate immune response to viral infection, at least in part through the activation of DEFB103, a human defensin that can inhibit muscle differentiation. Expand
DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1
The results suggest that up-regulation of both DUX4 and PITX1 in FSHD muscles may play critical roles in the molecular mechanisms of the disease. Expand
Facioscapulohumeral muscular dystrophy: consequences of chromatin relaxation.
The observations supporting the possibility of a developmental defect in facioscapulohumeral muscular dystrophy are discussed to provide a comprehensive overview of the current understanding of the disease mechanism. Expand
Antisense targeting of 3' end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach.
It is demonstrated that targeting either the mRNA polyadenylation signal and/or cleavage site is an efficient strategy to down-regulate Dux4 expression and to decrease the abnormally high-pathological expression of genes downstream of DUX4. Expand